Avidex Ltd - acquired by Medigene AG
Avidex was founded in 1999 seeking to become the world's leading T- cell receptor company based on a series of patents which protect its novel technologies. These technologies allow T-cell proteins to be produces as soluble and stable compounds which can be used both as protein pramaceuticals and for the discovery of new chemical entities.
Avidex was acquired by Medigene AG, a Frankfurt listed biotechnology company, in October 2006 (MDG.F)
"MediGene's vision is the expansion of the potentials in medicine by means of utilising biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biophamaceuticals company from research to drug development and commercialisation."